UBS sets USD 16.00 target for Ultragenyx Pharmaceutical stock

Published on 10/20/2026 at 19:25 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Ultragenyx agreed to sell a voucher for USD 203.00 million on October 14, 2026. RARE stock costs EUR 14.42 on October 20, 2026 in after-hours trading.

Analyst target and funding

UBS initiated coverage with a USD 16.00 target and a Neutral rating on October 14, 2026.
Ultragenyx agreed to sell a priority review voucher for USD 203.00 million on October 14, 2026.
Ultragenyx Pharmaceutical stock costs EUR 14.42 at Lang & Schwarz on October 20, 2026 at 7:16 p.m. CEST.

RARE, US90400D1081, Illustration mit AI erstellt.

Ultragenyx Pharmaceutical (ISIN US90400D1081) received a Neutral rating and a USD 16.00 price target when UBS initiated coverage on October 14, 2026, according to Markets Insider. The company also agreed to sell a priority review voucher for USD 203.00 million on October 14, 2026, and RARE stock was trading at EUR 14.42 at Lang & Schwarz on October 20, 2026 at 7:16 p.m. CEST.

UBS takes a cautious view

UBS cited two recent approvals while assigning the Neutral rating and target. Its view leaves limited room for upside when the USD 16.00 target is compared with the US share price cited in the analyst report.

The UBS coverage followed the approval of FAYUVI for mucopolysaccharidosis type IIIA and Genglycos for glycogen storage disease type Ia. The report described the commercial opportunities in both indications as limited, a counterweight to the regulatory progress.

Voucher sale adds funding

Ultragenyx said the USD 203.00 million transaction would provide non-dilutive funding for its rare disease pipeline. The agreement remains subject to customary closing conditions, including expiration of the applicable Hart-Scott-Rodino waiting period, according to the company release dated October 14, 2026, from Ultragenyx Pharmaceutical.

Revenue reached USD 214.00 million

For the second quarter of 2026, revenue was USD 214.00 million, up 28.50 percent from the prior-year quarter. Adjusted loss per share was USD 0.90, versus a consensus loss of USD 1.22, according to MarketBeat.

That quarterly revenue comparison gives the valuation debate a measurable operating anchor. Ultragenyx operates in biotechnology and develops treatments for rare and ultra-rare genetic diseases.

What comes next for RARE?

The next major investor reference is the companys commercial progress after the two approvals and the voucher agreements. The October 14 transaction was the second priority review voucher sale announced within one week, bringing the two agreed voucher prices to USD 413.00 million before transaction costs.

Stock remains a biotechnology watchpoint

Market capitalization stood at USD 1.5 billion on October 15, 2026. The Nasdaq-listed stock had a 52-week range of USD 12.73 to USD 39.89 on that date, keeping the analyst target, funding proceeds and execution of the approved therapies central to the investment case.

Ultragenyx Pharmaceutical stock was trading at EUR 14.42 at Lang & Schwarz on October 20, 2026 at 7:16 p.m. CEST. The further course of trading is shown by the continuously updated real-time quote of Ultragenyx Pharmaceutical stock.